Biotech Volatile Stcoks: TG Therapeutics (NASDAQ:TGTX), DARA Biosciences Inc (NASDAQ:DARA), Corcept Therapeutics Incorporated (NASDAQ:CORT), Prothena Corporation PLC (NASDAQ:PRTA), Coronado Biosciences Inc (NASDAQ:CNDO)

TG Therapeutics, Inc. (Nasdaq:TGTX), announced an agreement with Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) to license exclusive global rights to develop and commercialize Ligand’s IRAK4 inhibitor research program. Interleukin-1 Receptor Associated Kinase 4, referred to as IRAK4, is a key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldenström’s Macroglobulinemia, a rare B-cell cancer, as well as in a sub-set of patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia.TG Therapeutics, Inc. (NASDAQ:TGTX) weekly performance is 12.59%. On last trading day company shares ended up $9.93. Analysts mean target price for the company is $15.25. TG Therapeutics, Inc. (NASDAQ:TGTX) distance from 50-day simple moving average is 63.94%.

DARA BioSciences, Inc. (Nasdaq: DARA) announced that its Board of Directors has appointed current President and Chief Operating Officer (COO) Christopher G. Clement to President and Chief Executive Officer (CEO), effective immediately. David J. Drutz, M.D., the Company’s current CEO and Chief Medical Officer (CMO), will transition to the Executive Chairman of the Board of Directors while continuing to serve as CMO. In these roles, Dr. Drutz will provide ongoing leadership to DARA’s strategic planning, business development and educational product support activities relative to our customers and sales organization. Haywood D. Cochrane Jr. will assume the role of Vice Chairman. DARA Biosciences Inc (NASDAQ:DARA) shares fell -4.62% in last trading session and ended the day on $1.24. DARA Gross Margin is 50.00% and its return on assets is -110.90%. DARA Biosciences Inc (NASDAQ:DARA) quarterly performance is -57.68%.

Corcept Therapeutics (NASDAQ:CORT) Director G Leonard Baker, Jr. purchased 103,386 shares of Corcept Therapeutics stock on the open market in a transaction dated Wednesday, June 11th. The shares were purchased at an average cost of $2.32 per share, with a total value of $239,855.52. Following the acquisition, the director now directly owns 578,389 shares in the company, valued at approximately $1,341,862. The transaction was disclosed in a legal filing with the Securities & Exchange Commission. Corcept Therapeutics Incorporated (NASDAQ:CORT) shares moved down -4.47% in last trading session and was closed at $2.78, while trading in range of $2.73-$2.97. Corcept Therapeutics Incorporated (NASDAQ:CORT) year to date performance is -13.40%.

Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced that it has commenced an underwritten public offering of $100 million of its ordinary shares. All of the ordinary shares in the offering are to be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional $15 million of its ordinary shares. Prothena Corporation PLC (NASDAQ:PRTA) ended the last trading day at $23.11. Company weekly volatility is calculated as 8.17% and price to cash ratio as 2.59. Prothena Corporation PLC (NASDAQ:PRTA) showed a positive weekly performance of 0.65%.

On May 13,2014 Coronado Biosciences Inc (NASDAQ:CNDO) announced that it has initiated a Phase 2a clinical trial of TSO (Trichuris suis ova or CNDO-201) for the treatment of pediatric patients with autism spectrum disorder (ASD) at multiple centers in the United States. Coronado Biosciences Inc (NASDAQ:CNDO) weekly performance is -3.93%. On last trading day company shares ended up $1.71. Analysts mean target price for the company is $1.57. Coronado Biosciences Inc (NASDAQ:CNDO) distance from 50-day simple moving average is -1.71%.